Business
Press Release Aug 12 2021
Cipla Limited has informed the Exchange regarding a press release dated August 12, 2021, titled "Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol�� (Difluprednate Ophthalmic Emulsion 0.05%)".
About this update from Cipla Ltd
[{"type":"text","content":" Cipla Limited has informed the Exchange regarding a press release dated August 12, 2021, titled \"Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol�� (Difluprednate Ophthalmic Emulsion 0.05%)\". View Attachment","length":385,"tagName":"div"}]